Approval · Notice of Compliance 2235 · 2001
LOVENOX: Notice of Compliance 2235
Issued March 20, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2235
- Date
- March 20, 2001
- Company
- Aventis Pharma Inc.Laval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revised indication: prophylaxis of deep vein thrombosis (dvt) in medical patients bedridden due to acute cardiac insufficiency, acute respiratory failure and acute respiratory infections (excluding septic shock)
- Therapeutic class
- Anticoagulant/antithrombotic agent (low molecular weight heparin fragment)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LOVENOX | Not yet assigned | — |
Medicinal ingredients
- ENOXAPARIN SODIUM 40 MG per 0.4ML